The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery

被引：16
作者：
Holzhauser L. [1 ]
Kim G. [1 ]
Sayer G. [1 ]
Uriel N. [1 ]
机构：
[1] Department of Medicine, Division of Cardiology, University of Chicago, Chicago, IL
来源：
Current Heart Failure Reports | 2018年 / 15卷 / 4期
关键词：
Biomarkers; Heart failure; Left ventricular assist device (LVAD); Myocardial recovery;
D O I：
10.1007/s11897-018-0399-3
中图分类号：
学科分类号：
摘要：
Purpose of Review: Left ventricular assist device (LVAD) therapy serves as mainstay therapy for bridge to transplantation and destination therapy. Evidence is now mounting on the role of LVAD therapy as bridge to recovery. In the current review, we will summarize the data on biomarkers of myocardial recovery following LVAD implantation. Recent Findings: Myocardial recovery can occur spontaneously, following pharmacological intervention and in the setting of mechanical circulatory support such as LVAD. Several biomarkers such as B-type natriuretic peptide (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), ST2, etc. have been identified and are being used to guide medical therapy in heart failure (HF) patients. However, recent data raised concern that those biomarkers may not be helpful in managing heart failure patients in general, and as such questioned their use in the advanced heart failure population. At this point, the use of biomarker to identify patients with myocardial recovery during LVAD support has not been established, and LVAD explantation remains a decision driven by echocardiographic and hemodynamics improvement. Summary: HF biomarkers in monitoring myocardial and neurohormonal activation response to mechanical unloading and medical therapy could be valuable. However, at this time, there is inadequate evidence to select a single or a set of HF biomarkers to reliably identify patients bridged to recovery for LVAD explantation. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码：250 / 259
页数：9
相关论文
共 77 条
  • [1] Katz A.M., Maladaptive growth in the failing heart: the cardiomyopathy of overload, Cardiovasc Drugs Ther, 16, 3, pp. 245-249, (2002)
  • [2] Moss A.J., Hall W.J., Cannom D.S., Klein H., Brown M.W., Daubert J.P., Estes N.A., Foster E., Greenberg H., Higgins S.L., Et al., Cardiac-resynchronization therapy for the prevention of heart-failure events, N Engl J Med, 361, 14, pp. 1329-1338, (2009)
  • [3] Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., Et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators, N Engl J Med, 327, 10, pp. 669-677, (1992)
  • [4] Konstam M.A., Patten R.D., Thomas I., Ramahi T., La Bresh K., Goldman S., Lewis W., Gradman A., Self K.S., Bittner V., Et al., Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy, Am Heart J, 139, 6, pp. 1081-1087, (2000)
  • [5] Hoshikawa E., Matsumura Y., Kubo T., Okawa M., Yamasaki N., Kitaoka H., Furuno T., Takata J., Doi Y.L., Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy, Am J Cardiol, 107, 7, pp. 1065-1070, (2011)
  • [6] Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L., The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med, 352, 15, pp. 1539-1549, (2005)
  • [7] Drakos S.G., Kfoury A.G., Hammond E.H., Reid B.B., Revelo M.P., Rasmusson B.Y., Whitehead K.J., Salama M.E., Selzman C.H., Stehlik J., Clayson S.E., Bristow M.R., Renlund D.G., Li D.Y., Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart, J Am Coll Cardiol, 56, 5, pp. 382-391, (2010)
  • [8] Farris S.D., Don C., Helterline D., Costa C., Plummer T., Steffes S., Mahr C., Mokadam N.A., Stempien-Otero A., Cell-specific pathways supporting persistent fibrosis in heart failure, J Am Coll Cardiol, 70, 3, pp. 344-354, (2017)
  • [9] Diakos N.A., Selzman C.H., Sachse F.B., Stehlik J., Kfoury A.G., Wever-Pinzon O., Catino A., Alharethi R., Reid B.B., Miller D.V., Salama M., Zaitsev A.V., Shibayama J., Li H., Fang J.C., Li D.Y., Drakos S.G., Myocardial atrophy and chronic mechanical unloading of the failing human heart: implications for cardiac assist device-induced myocardial recovery, J Am Coll Cardiol, 64, 15, pp. 1602-1612, (2014)
  • [10] Diakos N.A., Navankasattusas S., Abel E.D., Rutter J., McCreath L., Ferrin P., McKellar S.H., Miller D.V., Park S.Y., Richardson R.S., Et al., Evidence of glycolysis up-regulation and pyruvate mitochondrial oxidation mismatch during mechanical unloading of the failing human heart: implications for cardiac reloading and conditioning, JACC Basic Transl Sci, 1, 6, pp. 432-444, (2016)
12345678